Tuesday, May 29, 2012
Theralase to Present at BioFinance 2012 Life Sciences Conference
Toronto, Ontario – May 29, 2012, Theralase Technologies Inc. (TSXV: TLT) announced today that Roger Dumoulin-White, President and CEO will present the latest corporate information at the BioFinance 2012 conference being held in Toronto, Ontario from May 29 to 30, 2012.
BioFinance is a leading life sciences investor conference in Canada which showcases more than 60 diverse life science companies and the investment opportunities that they present. BioFinance 2012 also features 17 investor presentations that are aimed at addressing specific financing and management related issues relevant to life science industries.
Theralase’s presentation will take place Wednesday, May 30th at 3:00 pm in Company Presentation Room 1 at the St. Andrew’s Club and Conference Center. Mr. Roger Dumoulin-White, President and CEO of Theralase will present on the strategic direction and recent accomplishments of the company followed by a short Q&A period and longer one-on-one meeting period.
In other news, Mr. Dumoulin-White was recently interviewed on the TV show “The Next Biggest Winner” which is due to air on Ichannel on Tuesday, June 5th at 7:30pm. The Ichannel has over 1.3 million affluent Canadian subscribers who look to its business programming for investment opportunities. For a sneak preview, please visit http://youtu.be/y8VT6Rwp_gY
About Theralase Technologies Inc.:
Theralase Technologies Inc., founded in 1995, designs, develops, manufactures and markets patented, superpulsed laser technology utilized in biostimulation and biodestruction applications. Theralase technology is internationally approved in the safe and effective treatment of pain, inflammation and for the regeneration of tissue in neural muscular skeletal conditions in both humans and animals. Theralase is also researching and developing patented Photo Dynamic Compound (PDC) technology that is focused at targeting and destroying specific cancers, bacteria and viruses when light activated by Theralase’s proprietary and patented laser technologies.
For further information please visit www.theralase.com, regulatory filings may be viewed by visiting www.sedar.com.
This press release contains forward-looking statements which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual results could differ materially from those projected herein. The Company disclaims any obligation to update these forward-looking statements.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchanges) accepts responsibility for the adequacy or accuracy of this release.
For More Information, please contact:
Roger Dumoulin - White,
President & CEO
416-447-8455 ext. 225
Chief Financial Officer
416-447-8455 ext. email@example.com